Pfizer – Advances in the Management of Ulcerative Colitis (UC) – RFP
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: inquire with unit
Memorial Deadline: Friday 2nd, August 2024
External Deadline: Wednesday 7th, August 2024
Description
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.
For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.
Date RFP Issued: June 12, 2024
Geographic Scope: Europe, Canada, Australia, New Zealand, Israel, India, Mexico, Turkey, Saudi Arabia, Brazil, Taiwan
Clinical Area: Ulcerative Colitis (UC)
Link to full RFP: Advances in the Management of Ulcerative Colitis (UC)
Application Due Date: August 7, 2024
Specific Area of Interest: Projects that will be considered for Pfizer support will focus on:
- – S1P receptor modulators mechanism of action (MoA) in UC
- – Oral Small Molecules (S1P receptor modulators and/or JAK inhibitors) in clinical management of moderate to severe UC and placement in the treatment algorithm
- – S1P receptor modulators pre-first dose assessment and current clinical management standard of care
- – Burden of disease and unmet needs in adolescents / young patients with UC and role of transition clinic.
– Burden of disease, unmet needs and treatment landscape in isolated proctitis
Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to Amanda Stein, Grant Officer (amanda.j.stein@pfizer.com).8